<DOC>
	<DOCNO>NCT01452854</DOCNO>
	<brief_summary>The purpose study look chemotherapy treatment ( Temozolomide , also call Temodar ) affect process ovarian age measured decline ovarian follicle count , patient Low Grade Glioma ( LGG ) . It important know different patient factor Temozolomide influence rate ovarian age woman LGG good long-term survival rate . This allow well counsel effect particular chemotherapy agent fertility woman .</brief_summary>
	<brief_title>Ovarian Aging Low Grade Glioma ( LGG ) Treated With Temozolomide</brief_title>
	<detailed_description>Understanding Temozolomide influence ovarian age would important information physician predict possibility infertility ( inability become pregnant ) follow recovery Temozolomide treatment . Physicians would like provide good individualized recommendation cancer patient regard timing plan treatment future pregnancy . We compare data woman treat Low Grade Glioma Temozolomide similar group woman unaffected cancer cancer treatment .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Premenopausal woman age 1844 newly diagnose LGG Patients fulfill inclusion criterion UCSF Protocol Number : CC # 99102 `` A Phase II Study Temozolomide ( TEMODAR ) Treatment Adult Patients Supratentorial Low Grade Glioma '' Patients histologically proven supratentorial low grade glioma . Patients may may surgical resection . Patients must expect live length study Patients must able provide inform consent accord institutional guideline . Prior ovarian resection , unilateral bilateral oophorectomy , hysterectomy radiation pelvic region . Pregnancy breast feed . Diagnosis another malignancy , unless patient diagnose least 2 year earlier diseasefree least 6 month follow completion curative intent therapy follow exception : Patients treat nonmelanoma skin cancer , situ carcinoma , cervical intraepithelial neoplasia , regardless diseasefree duration , eligible study definitive treatment condition complete . Any significant concurrent disease , illness , psychiatric disorder would compromise patient safety compliance , interfere consent , study participation , follow , interpretation study result . Patients systemic fungal , bacterial , viral , infection control ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) . Patient , time signing informed consent , regular user ( include `` recreational use '' ) illicit drug , substance abuse recent history ( within last year ) drug alcohol abuse Patient history current evidence condition , therapy , lab abnormality might confound result study , interfere patient 's participation full duration study best interest patient .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>LGG</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Temodar</keyword>
	<keyword>Ovarian Aging</keyword>
	<keyword>Infertility</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>